Suven Pharmaceuticals and Cohance Lifesciences Join Forces in Transformative Merger

Suven Pharmaceuticals, a leading Indian pharmaceutical company, announced on Thursday that it will merge with Cohance Lifesciences, a contract development and manufacturing organization (CDMO) platform. The merger is a significant step in Suven's journey of growth and its aim to become a respected integrated CDMO player.

Representative image

Merger Details

Under the proposed scheme of amalgamation, all shareholders of Cohance will receive 11 shares of Suven for every 295 shares held in Cohance. The new shares of Suven will be traded on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).

Transaction Timeline

The transaction is expected to be completed over the next 12-15 months, subject to receiving all necessary shareholder and regulatory approvals.

Strategic Significance

Suven's Executive Chairman, Annaswamy Vaidheesh, expressed excitement about the merger, calling it a transformative step in the company's growth. The merger will enable Suven to expand its capabilities and become a leading integrated CDMO player.

Advent International's Involvement

In December 2022, Suven Pharmaceuticals' promoter, the Jasti family, sold a 50.1% stake in the company to global private equity investor Advent International. Advent International also launched Cohance Lifesciences in 2022 as a new brand identity for its API (active pharmaceutical ingredient) and CDMO platform.

Shareholding Structure

After the merger, Advent entities will hold a 66.7% stake in the combined entity, while public shareholders will own the remaining 33.3%.

Cohance Lifesciences Platform

The Cohance Lifesciences platform comprises three of Advent's portfolio companies: RA Chem Pharma, ZCL Chemicals, and Avra Laboratories.

The merger between Suven Pharmaceuticals and Cohance Lifesciences is a significant development in the Indian pharmaceutical industry. It will create a leading integrated CDMO player with enhanced capabilities and a strong market position.